Canada markets closed

CELC Jun 2024 22.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.90000.0000 (0.00%)
At close: 03:11PM EDT
Full screen
Previous Close0.9000
Open0.9000
Bid0.0000
Ask0.7500
Strike22.50
Expire Date2024-06-21
Day's Range0.9000 - 0.9000
Contract RangeN/A
Volume5
Open Interest6
  • GlobeNewswire

    Celcuity To Participate in Jefferies Global Healthcare Conference

    MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on Thursday, June 6, 2024. A live webcast of the event will be available using this we

  • GlobeNewswire

    Celcuity Announces Pricing of Underwritten Common Stock Offering

    MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share. All of the securities are to be sold by Celcuity. Investors who have agreed to purchase shares in the offering include BVF Partners L.P., a U.S.-based healthcare focused investor, Vivo Capit

  • GlobeNewswire

    Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

    The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistantReceived an additional term loan of approximately $62 million in conjunction with an amendment to an existing debt facility agreement MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for o